Stockreport

AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of)  (TAK) 
PDF - Takeda to receive exclusive option to license global rights to ACI-24.060, a potential first-in-class active immunotherapy designed to delay or slow Alzheimer’s diseas [Read more]